Trials / Completed
CompletedNCT02364362
A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Docetaxel Plus Famitinib Versus Docetaxel Plus Placebo in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. This study assessed the safety and maximum tolerated dose of continuous daily treatment with Famitinib plus docetaxel (60 mg/m\^2, every 3 weeks) in patients with Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) to determine the recommended dose for the Phase II trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | famitinib L + docetaxel | famitinib 15mg qd + docetaxel 60 mg/m\^2 |
| DRUG | famitinib M + docetaxel | famitinib 20mg qd + docetaxel 60 mg/m\^2 |
| DRUG | famitinib H + docetaxel | famitinib 25mg qd + docetaxel 60 mg/m\^2 |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2015-02-18
- Last updated
- 2019-01-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02364362. Inclusion in this directory is not an endorsement.